NASDAQ
11.00USD
-0.02 (-0.18%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
99.5M
P/E
—
EPS
—
Beta
0.57
52W range
4.52-12.1
Day range
10.76–11.01
Open
11.00
Prev close
11.02
Volume
9.7K
Avg volume
29.7K
Dividend
0.00
IPO
1987-05-05
https://seekingalpha.com/article/4925137-immucell-stock-first-defense-with-better-execution · 7/24/2026+0.60
https://www.zacks.com/stock/news/2926104/immucell-q1-earnings-rise-y-y-as-sales-climb-on-strong-demand?cid=CS-STOCKNEWSAPI-FT-microcap_article|earnings-2926104 · 5/25/2026+1.00
https://www.globenewswire.com/news-release/2026/04/13/3272914/0/en/ImmuCell-Bolsters-its-Innovation-Strategy-with-Appointments-of-Dr-Gilles-Guillemette-and-Dr-Anthony-DiMarco-to-the-Board-and-Moves-to-a-Smaller-Board-of-Independent-Directors.html · 4/13/2026+0.90
https://www.defenseworld.net/2026/03/07/immucell-q4-earnings-call-highlights.html · 3/7/2026+0.60
https://www.globenewswire.com/news-release/2026/01/08/3215792/0/en/ImmuCell-Announces-Preliminary-Unaudited-Sales-Results-for-Q4-and-Full-Year-of-2025.html · 1/8/2026
https://www.globenewswire.com/news-release/2025/12/24/3210388/0/en/ImmuCell-Announces-Strategic-Focus-on-First-Defense-After-Receiving-an-FDA-Incomplete-Letter-for-Re-Tain.html · 12/24/2025-0.20
https://www.globenewswire.com/news-release/2025/11/06/3183088/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Quarter-Ended-September-30-2025.html · 11/6/2025+0.00
https://www.globenewswire.com/news-release/2025/11/04/3180845/0/en/ImmuCell-Announces-Onboarding-of-New-CEO-and-Related-Management-Changes.html · 11/4/2025+0.20
https://www.zacks.com/stock/news/2740928/immucell-swings-to-q2-profit-on-strong-sales-shares-still-slide?cid=CS-STOCKNEWSAPI-FT-microcap_article|earnings-2740928 · 8/21/2025-0.30
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
